Article info
PDFTechnology and guidelines
Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia: NICE technology appraisal guidance
- Dr D Barnett, National Institute for Health and Clinical Excellence, UK; david.barnett{at}nice.org.uk
Citation
Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia: NICE technology appraisal guidance
Publication history
- Accepted January 8, 2008
- First published April 14, 2008.
Online issue publication
March 15, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
2008 BMJ Publishing Group and British Cardiovascular Society